The role of integrins in resistance to BTK inhibitors in CLL

Evaluating the role of BTK inhibitors in CLLПодробнее

Overcoming resistance to BTK inhibition in CLLПодробнее

Resistance to BTK Targeted Therapy in CLLПодробнее

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

The role of next-generation BTK inhibitors in the treatment of CLLПодробнее

Resistance to BTK Inhibitors in B-Cell MalignanciesПодробнее

Understanding and overcoming resistance to BTK and BCL-2 inhibitors in CLLПодробнее

Resistance to acalabrutinib in CLL is mediated by BTK mutationsПодробнее

BCR Inhibitors in CLL and LymphomaПодробнее

Pirtobrutinib resistance in CLL: early findingsПодробнее

Mechanisms of resistance to targeted therapies in CLLПодробнее

Resistance to Therapy in CLLПодробнее

Rationale for BTK Inhibition in CLLПодробнее

CLL: BTK Inhibitors in Hematologic Oncology Pathways - Pathway-Guided ChoicesПодробнее

Non-covalent vs covalent BTK inhibitors in CLLПодробнее

The role of the protein MARCKS in CLL response to BTK inhibitorsПодробнее

Next-Generation BTK inhibitors and their role in the CLL treatment landscapeПодробнее

The current role of continuous BTK inhibitors in CLL treatment: benefits and drawbacksПодробнее